Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Liabilities and Shareholders Equity (2016 - 2025)

VYNE Therapeutics' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $30.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 54.92% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $198.2 million, down 38.34%, while the annual FY2025 figure was $30.2 million, 54.92% down from the prior year.
  • Liabilities and Shareholders Equity reached $30.2 million in Q4 2025 per VYNE's latest filing, down from $44.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $149.2 million in Q1 2021 to a low of $19.3 million in Q3 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $66.8 million, with a median of $64.3 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 58.93% in 2023, then soared 295.48% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $67.0 million in 2021, then crashed by 39.21% to $40.8 million in 2022, then skyrocketed by 139.67% to $97.7 million in 2023, then tumbled by 31.51% to $66.9 million in 2024, then tumbled by 54.92% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Liabilities and Shareholders Equity are $30.2 million (Q4 2025), $44.7 million (Q2 2025), and $56.4 million (Q1 2025).